Dr Reddy's Laboratories Launches Generic Drug to Treat Multiple Sclerosis in US
The company's product is a therapeutic equivalent generic version of Biogen's Tecfidera delayed-release capsules, the Hyderabad-based drug firm said in a statement. According to IQVIA Health data, the Tecfidera brand and generic market had sales of around USD 3.8 billion (about Rs 28,000 crore) in the US for the most recent twelve months ending in June 2020.
New Delhi, September 26: Dr Reddy's Laboratories on Saturday said it has launched Dimethyl Fumarate delayed-release capsules, used to treat multiple sclerosis (MS), in the US market.
The company's product is a therapeutic equivalent generic version of Biogen's Tecfidera delayed-release capsules, the Hyderabad-based drug firm said in a statement. COVID-19 Vaccine Update: Russia to Supply 100 Million Doses of Sputnik V to India's Dr Reddy's Laboratories.
According to IQVIA Health data, the Tecfidera brand and generic market had sales of around USD 3.8 billion (about Rs 28,000 crore) in the US for the most recent twelve months ending in June 2020.